GlaxoSmithKline plc And SkyePharma PLC: A Match Made In Heaven?

GlaxoSmithKline plc (LON: GSK) and SkyePharma PLC (LON: SKP) offer the perfect blend of both growth and income.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is a great stock for any portfolio. Indeed, the company has all the best qualities you could ask for — a high dividend yield, attractive valuation healthy balance sheet, dominant market position and a reliable cash flow.

At present, Glaxo’s shares support a dividend yield of 5.1%. The company trades at a forward P/E of 16.9, which may seem high, but Glaxo trades at a significant discount to its international peer group. 

Lacking growth

Still, one thing Glaxo lacks is growth. The company’s earnings per share are set to fall 5% next year and City analysts expect the company to report moderate EPS growth of 5% during 2016 — nothing to get excited about. 

That’s where SkyePharma (LSE: SKP) comes into the picture. Skye has worked with Glaxo in the past. Some of the company’s key technologies are designed to help the delivery of oral and inhalation pharmaceutical products.

Glaxo is a specialist in oral treatments. The global pharma group currently produces two treatments that use technology licensed by Skye. Skye’s royalty payments from these treatments are capped at £9m per annum. 

Rapid growth

While Glaxo’s glacial growth rate may put some investors off, Skye’s most attractive quality is the company’s projected growth rate. City analysts expect the company’s earnings per share to expand at a high single-digit rate over the next three years, as sales of the company’s key products continue to expand.

In particular, Skye has launched eight new products in the past three years and several more are still in the pipeline. These include SKP-2075, for chronic obstructive pulmonary disease and Soctec™, a concept for a novel, proprietary gastro-retentive drug delivery platform.

Skye is also pumping cash into research and development. R&D spending totalled £0.5m during 2013 but then jumped to £4.5m for fiscal 2014 and is expected to hit £10m during 2015.  With a strong pipeline of treatments under development and more cash being devoted to R&D spending, Skye is charting a course for rapid growth over the next decade or so.

Unfortunately, with such bright growth prospects, Skye isn’t cheap. The company currently trades at a forward — 2015 — P/E of 15.2, falling to 14.4 during 2016. 

Nevertheless, Skye deserves a premium valuaion and I wouldn’t rule out a bid from a large peer, like Glaxo, in the near future. 

Foolish summary

So, if you’re looking for a dynamic growth and income pharma duo for your portfolio, Glaxo and Skye look to be the perfect combination. While Glaxo offers income, Skye is growing rapidly and the company’s increasing R&D budget will only serve to drive further growth in the future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »